REGISTER
JSCO 2026 Opens in Kobe With AI Precision Oncology and ASCO-ESMO-UICC Joint Sessions
The 64th Japanese Society of Clinical Oncology (JSCO) Annual Meeting will be held Oct 22-24, 2026, at the Kobe Convention Center in Kobe, Japan, under the theme “One Team to Conquer Cancer.” Congress President Koji Kono of Fukushima Medical University leads the meeting. The program includes precision medicine symposia with ASCO, ESMO, and UICC, four JSCO Frontier sessions spanning precision oncology, colorectal cancer, and gastrointestinal cancers, and the concurrent 6th AOS2026 congress.

The 64th Japanese Society of Clinical Oncology (JSCO) Annual Meeting will be held Oct 22 to 24, 2026, at the Kobe Convention Center in Kobe, Japan.

Congress President is Koji Kono, MD, PhD. He currently serves as a board member and vice president of Fukushima Medical University, and as professor and head of the Department of Gastrointestinal Surgery at the same institution. This is the second time Fukushima Medical University has hosted the JSCO Annual Meeting, following the 52nd meeting in 2014.

The meeting theme is “One Team to Conquer Cancer.” Against the backdrop of cancer genomics, immunotherapy, robot-assisted surgery, and artificial intelligence, the meeting will bring together clinicians, researchers, and health professionals to discuss clinical topics including photoimmunotherapy, immune checkpoint inhibitor treatment, circulating tumor DNA (ctDNA)-guided follow-up, and genomic biomarkers.

Article Key Points

- Meeting type: preview of the 64th JSCO Annual Meeting, Oct 22-24, 2026, Kobe Convention Center, Japan

- Theme: “One Team to Conquer Cancer”; Congress President Koji Kono, MD, PhD, Fukushima Medical University

- Scientific focus: photoimmunotherapy, immune checkpoint inhibitors, ctDNA-guided follow-up, genomic biomarkers

- International component: joint symposia with ASCO, ESMO, and UICC, plus Fellow reports and mentor symposia

- Four JSCO2026 Frontier sessions cover precision oncology, multi-tumor topics, colorectal cancer, and GI/head and neck

- Colorectal Frontier topics scheduled include MSI-H/dMMR, BRAF V600E, surgical outcomes, and ctDNA-based restratification

- AOS2026 runs concurrently with 9 symposiums and 32 oral presentations on immunotherapy, precision medicine, and AI

- Evidence status: meeting preview; no results have been presented, and these topics are scheduled, not reported findings

The International Symposium Sessions

On the morning of Oct 22, the President’s Session: International Symposium for Precision Medicine will address AI-driven precision medicine, national precision oncology platforms, and antibody-drug conjugate development.

ESMO President Fabrice Andre will then deliver a keynote address. The ESMO-JSCO Joint Symposium will focus on multimodal treatment of gastrointestinal cancers, with topics including the 2026 ESMO guideline update, colorectal cancer treatment in the era of molecular residual disease, and upper gastrointestinal cancer strategies.

On the afternoon of Oct 23, ASCO President Eric Jay Small will deliver a keynote address. The ASCO-JSCO Joint Symposium that follows will address esophageal cancer and genitourinary tumors. The ASCO Mentors Symposium extends the discussion to anticancer drug dose derivation, the next wave of research priorities, and central nervous system metastasis in breast cancer. ASCO/JSCO and ESMO/JSCO Fellow Reports are also scheduled, so international collaboration covers both scientific topics and early-career exchange.

The JSCO Frontier Sessions

The four JSCO2026 Frontier sessions form a meeting-wide series of frontier research rather than a single disease-focused track. In the Congress President’s address, the series is described as a window for conveying Japanese frontier cancer research to the world. The sessions span precision oncology, breast, gynecologic and genitourinary malignancy, colorectal cancer, and gastrointestinal and head and neck cancer, connecting biomarkers, clinical trials, surgery, and pharmacotherapy.

Frontier 1 | Emerging Frontiers in Precision Oncology for Solid Tumors

Oct 22, 14:10-15:10, Room 10

Four scheduled presentations concern pan-cancer multi-omics in early-onset solid tumors, CDK pathway alterations, postoperative ctDNA molecular residual disease dynamics, and multi-cancer early detection models. The shared question is how to move omics and liquid biopsy from signal discovery to risk stratification and follow-up decisions.

Frontier 2 | Breast, Gynecologic, Genitourinary, and Other Malignancies

Oct 22, 15:20-17:20, Room 10

This session includes 8 scheduled topics covering HR+/HER2- metastatic breast cancer, a Japanese subgroup of locally advanced cervical cancer, FR-alpha biomarkers in ovarian cancer, the immune microenvironment in urothelial carcinoma, ctDNA-guided treatment of muscle-invasive bladder cancer, and renal cell carcinoma. It is better understood as a cross-tumor session on biomarker-to-treatment selection than as a general multi-tumor program.

Frontier 3 | New Frontiers in Colorectal Cancer: Insights from Clinical Trials, Surgery, and Biomarkers

Oct 24, 8:20-9:50, Room 10

Six scheduled studies place clinical trials, surgery, and biomarkers on a single decision pathway, addressing MSI-H/dMMR, BRAF V600E mutation, surgical outcomes in metastatic colorectal cancer, and further stratification of recurrence risk in patients with postoperative ctDNA-negative disease.

Frontier 4 | Gastrointestinal Cancers and Head and Neck Cancer

Oct 24, 13:50-15:05, Room 10

Five scheduled topics cover perioperative supportive care in esophagogastric junction cancer, treatment of CLDN18.2-positive gastric and gastroesophageal junction cancer, five-year survival analysis of CheckMate 649, first-line treatment research in metastatic colorectal cancer, and radiotherapy techniques for preventive treatment in locally advanced head and neck squamous cell carcinoma.

The Concurrent AOS2026 Program

The 6th Asian oncology congress, AOS2026, will be held concurrently with JSCO 2026. Its detailed English program sets out 9 symposiums and 32 oral presentations, covering immunotherapy, precision medicine based on integrative genomic analysis and ctDNA, minimally invasive surgery, basic and translational research, AI oncology, novel radiotherapy, and topics including healthcare economics, work-life balance for oncologists, and treatment of elderly cancer patients in Asia.

Several experts from institutions in mainland China will participate in AOS symposiums and oral presentations. Ying Wang, vice chair of the Chinese Anti-Cancer Association (CACA) and secretary-general of the Asian oncology congress, will chair two symposiums, “Current Status of Immunotherapy” and “AI Application in Oncology.” Li Zhang of the Sun Yat-sen University Cancer Center is listed in AOS Symposium 1, scheduled to report on treatment strategies and clinical progress for bispecific antibodies in Chinese lung cancer.

Additional Sessions

- Nature Masterclass 1 and 2 address what makes a great paper and publishing with Nature Portfolio, focusing on medical writing and international academic publication.

- The Invited Speaker Series: Forefront in Onco-Surgery, on Oct 24 from 10:00 to 11:30, covers gastric cancer surgery, metabolic and bariatric surgery with cancer prevention, perioperative immunotherapy in esophageal cancer, and national cancer control experience from Korea.

- The UICC-JSCO Joint Symposium is scheduled for Oct 24 from 15:30 to 17:00.

- The meeting also includes regular oral presentations, poster sessions, education sessions, and organ-specific tracks.

The full program and any subsequent changes should be confirmed against the official JSCO 2026 website and the official meeting app.

0
0
Loading